Survival of patients with de novo AML treated on St Jude trials. (A) EFS and (B) OS of patients with de novo AML (excluding those with Down syndrome or APL) treated on St Jude trials during the years indicated. AML02 was multi-institutional, whereas earlier studies were single institution.